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Abstract 
  
Background  
Glioma is considered to be a rare type of cancer of the central nervous system (CNS) 
with the average age-adjusted incidence rate of 3.4 per 100, 000 population.  Moreover, 
gliomas are the most common type of malignant brain tumors among adult population. They 
account for about 80% of all diagnosed brain tumors originating from brain parenchyma. 
Despite achievements in medical treatment and technologies glioblastoma patients still have 
poor prognosis with 3-5% of surviving patients after 12-15 months following standard 
therapy. In addition, recent studies highlight importance of blood, and molecular markers in 
predicting presence of gliomas. 
Aims of the study  
Primary aim of the study is to investigate the association of isocitrate dehydrogenase 
(IDH) mutation with the molecular markers of tumor tissue, and its association with the 
survival time of glioma patients.  
Methodology 
This is a historical cohort study that was performed using secondary data provided by 
National Center for Neurosurgery (NCN) (Astana, Kazakhstan). The participants of the study 
were between 2009-2012. Bivariate analysis was performed between variables survival status 
of patients (status) and each predictive variable. The Kaplan-Meier method was used to 
analyze median survival time between the patients, and to compare their overall survival 
length. IDH effect was tested by building a Cox-regression model, adjusting with each 
explanatory variable 
Results 
190 patients were included in the study. Mean age of the participants was 43±12.8 years, 
and there was approximately an equal distribution of gender of the participants: 107 patients 
were male (56.3%) and 89 were female (43.7%). The glioma grade (G) variable was found to 
 
 
be significantly associated with survival time with the p=0.0433. Red Cell distribution width 
(RDW) was also significantly associated with survival status (p=0.011). Results of Cox-
regression revealed no significant predictors in multivariate analysis.  Unadjusted HR of dying 
among glioma patients with IDH versus without IDH was found to be HR 1.28 (95% CI: 0.790; 
1.901). Final survival model included only IDH mutation, age and gender variables. 
 
 
Conclusion  
 
 
Similar to other studies, current study found a significant association between survival 
status of the patients compared to the stage of the glioma grade. It should be highlighted that 
significant associations were found between IDH and blood markers. For example, NLR 
(p=0.046), ESR (p=0.002), PLT (p=0.021), and RDW (p=0.0034) were significantly associated 
with IDH mutation genes among glioma patients.  
No significant predictors of survival of glioma patients were found in this study, mainly 
due to lack of data. We suggest that absence of information on tumor size, tumor location, or 
important clinical interventions (such as chemotherapy) can be important confounding factors 
that should be taken into account in further studies.  
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1. Introduction  
 
1.1 Background/ Literature Review 
  
Glioma is considered to be a rare type of cancer of the central nervous system (CNS) 
with the average age-adjusted incidence rate of 3.4 per 100, 000 population (19, 20).  
Moreover, gliomas are the most common type of malignant brain tumors among adult 
population.  They account for about 80% of all diagnosed brain tumors originating from 
brain parenchyma (31). It was reported that 15% of all CNS and primary brain neoplasms 
account for glioma. According to World Health Organization (WHO), malignant gliomas are 
subcategorized to III/IV grades, and these grades are assigned depending on certain clinical 
pathological characteristics, such as mitotic activity, vascular proliferation, nuclear atypia, 
and outcome of the treatment (4). 
Although gliomas occur almost exclusively in the brain, they also might appear in the 
cerebellum, spinal cord, and in the brain stem. According to literature, 61% of all gliomas 
can be found on the four lobes of the brain: frontal (25%), temporal (20%), parietal (13%), 
and occipital (3%) (1). Historically, gliomas were considered to originate from glial cells, 
but modern evidences suggest that they might result from multiple cell types with neural-
stem like properties (14). 
Studies found that the average age for the development of glioblastoma is 64 years, 
but malignant glioblastoma might occur in any age groups, even among children (21). In 
addition, glioblastoma has 4 extreme degrees and malignancy, which more often occurs 
among people of working age after 40 years (7). Ellor, Pagano-Young, & Avgeropolous, 
2014 argue that the risk of glioblastoma is higher in men comparing to women (risk ratio 
1.6:1), and glioma rate was found to be higher among Caucasian ethnic group compared to 
other ethnicities.  
Despite achievements in medical treatment and technologies, glioblastoma patients 
still have poor prognosis with 3-5% of surviving patients after 12-15 months following 
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standard therapy (10). Previous studies  identified that factors such as: tumor size, assigned 
treatment, age, mental status, tumor grade, performance score, and  surgical resection size 
were consistently identified as prognostic factors of glioma patients overall survival (9,12) 
 Studies revealed that blood-based biomarkers for any given malignant gliomas may 
give approximate information regarding health status of the patient, and about burden of the 
tumor (22). Dynamic characteristics of the marker testing can be described with ability to 
proportionally and perfectly reflect the tumor burden. Accurately assessed specific markers 
can be identical to unique characteristics of the tumor itself (e.g., circulating tumor specific 
DNA or tumor cells). However, changes of turnover rates of cells, variability in half-life of 
plasma markers, and obtaining different therapies after surgery might significantly affect 
marker characteristics in blood (20, 26).  
Previous studies revealed that blood-based biomarkers are not always perfect.  It 
becomes clear while taking into account routinely usage of blood-based biomarkers for other 
cancer types investigation.  For instance, PSA (prostate-specific antigen) level can change 
dramatically in patients who had bacterial prostatitis, but markers still may provide essential 
information about cancer progression, and about tumor response (19,26). Several pilot 
studies revealed that circulating tumor DNA can be detected after blood tests among patients 
with malignant gliomas (15, 20, 26).  
In addition, recent studies show that mutated IDH-1 DNA can also be found in the 
plasma of patients with IDH-1 positive gliomas. Therefore, researchers concluded that 
relationship exists between blood-brain barrier disruption, and IDH-1 DNA detectability (14, 
26). For instance, results of meta-analysis of 165 studies conducted by Chen et al., 2016 
confirmed association of IDH mutation with overall survival of glioma patients (27). Many 
recent studies interested in anti-angiogenic agents for investigational therapies of 
glioblastoma, pro-angiogenic proteins have mostly considered circulating proteins in glioma 
investigation. Vascular endothelial growth factor (VEGF) is relatively large protein 
weighing 38.3 kDA, and initial function of this factor in physiology is to stimulate growth of 
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endothelial cells. In addition, circulating levels of the VEGF was analyzed in several 
prospective studies of glioma, and they found to be significantly associated with glioma 
patients’ survival (3, 26).  
Numerous studies revealed the association of chronic inflammation with high 
susceptibility for cancer diagnosis and progression (32). Inflammatory blood markers such 
as: neutrophil-to-lymphocyte ratio (NLR), and platelet count (PLT), red cell distribution 
width (RDW) has been proposed for prediction of glioma patient’s survival (3, 5, 32). The 
most studied blood count NLR was found to be relevant in many cancer studies (2, 29). 
Neutrophils and lymphocytes constitute a significant share of immune cells participating in 
inflammatory processes. In the context of cancer studies, NLR were proved to influence both 
pro-and antitumor procedures offering a dual mode of activation (28).  Red cell distribution 
width (RDW) was considered as an important predictive blood parameter in various chronic 
inflammatory conditions and cardiovascular pathologies. However, there is limited number 
of studies that investigated importance of RDW in glioma patients’ survival (5). Platelet 
count (PLT) is one of the convenient blood parameter that may serve as predictor for 
patient’s survival. Initially, the main function of PLT is to ameliorate damaged tissues by 
evolving inflammatory cells.  However, under chronic inflammation environment PLT 
stimulates growth of tumor, and studies found that PLT was highly correlated with PLT and 
NLR (32). It is believed that molecular markers can be useful for prognosis of glioma. 
Considering the availability of preoperative molecular and blood assays, such parameters 
can be essential to assess their effect on survival of glioma patients.   
 
1.2 Risk factors and clinical presentation of disease 
  
Results of different studies conducted to identify specific associative factors of 
glioblastoma with occupational and environmental exposure are still inconclusive. Wrench et 
al., in 2002 concluded that ionizing radiation is one of the few well-known risk factors for 
glioma development (33). Regarding other environmental exposures such as pesticides, vinyl 
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chloride, smoking, synthetic rubber manufacturing, and oil refining, these are found to be 
poorly associated with the development of glioma.  It should also be highlighted that, 
potential risk factors as electromagnetic fields, formaldehyde, and nonionizing radiation 
produced by cell phones have not been found to lead to glioblastoma (4). The risk of glioma 
was found to be higher among specific genetic diseases, such as tuberous sclerosis, Turcot 
syndrome, Li-Fraumeni syndrome, however, heredity of the disease is counted to be less than 
1% among glioblastoma patients (7, 5). Effects of serious head injuries or traumas were 
studied for a long time to investigate its relationship with gliomas (4,5). The results, 
however, are ambigious: some studies revealed a connection between head injury and 
meningioma, but no link between head trauma and glioma (5,6). Brain tumors are 
characterized to be more common among adult population. Nevertheless, people of any age 
group are susceptible to the development of the brain tumor (1). Regarding gender of 
patients, the risk of developing gliomas is generally higher among men relatively to women. 
However, there are specific types of brain tumors such as meningioma, which are more 
common among female population (16). 
Presentation of patients with newly diagnosed glioblastoma may differ regarding the 
size and location of tumor, and anatomic characteristics of evolved part of the brain (5).   
Often patients are characterized by increased intracranial pressure syndromes, including 
focal or progressive neurological deficit, and headache.  On average 25% of patients with 
glioma have reported seizure symptom, but this might increase up to 50% at later stages of 
brain tumor (20).   Modern standard of treatment of glioblastoma represents prescription of 
antiepileptic drugs (AEDs) for patients reporting seizure. However, routine use of AEDs for 
glioblastoma treatment is not recommended (4). Overall, glioblastoma patients often report 
headache, confusion, memory loss, focal neurologic deficits, and change of personality or 
seizures (16). 
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1.3 Diagnostics and treatment 
  
Treatment of the newly diagnosed glioma demands well-organized multidisciplinary 
approach. Primary diagnostic visualization of glioma includes magnetic resonance imaging 
(MRI), or computed tomography (CT) scan.   Today standard therapies for treatment of 
glioma include maximal safe surgical resection, followed by concurrent radiation with 
temozolomide, and oral chemotherapy, and finally with adjuvant chemotherapy with 
temozolomide (4,15). Complete surgical resection and extensive methods of treating 
glioblastoma are difficult because of the frequent invasive characteristics of tumor and its 
location on mostly eloquent parts of brain responsible for control senses, speech, and motor 
function of patient.  High level of invasiveness of tumor, surgical resection of the mass 
cannot be curative way, and cells of infiltrating tumor may remain within the surrounded 
brain by leading to further progression of disease or its reoccurrence (9). Novel technologies 
still have their limitations due to cost, need for specialized equipment and operators, and 
surgery suits.  
 
1.4 Situation in Kazakhstan 
 
Statistics of the incidence of glioblastoma in Kazakhstan are consistent with the 
worldwide data, with 3.0±0.04 rates per 100,000 people (30). According to Akshulakov et 
al., 2009, the number of patients registered with glioblastoma increased by 1.8 times 
between 1996 and 2007. According to statistical data for previous 10 years, highest rates of 
incidence for glioblastoma (from 4.8 to 5.8 per 100,000 population) occurred in Pavlodar, 
Kyzylorda, East Kazakhstan, and Almaty regions. Morbidity among males doubled within 
the last decade with the incidence rate 4.2±0.24 per 100,000 population, opposed to the 
beginning of the century 2.0±0.17 per 100,000 population. The incidence rate among women 
also increased from 1996 to 2007 (from 1.9 to 3.3 per 100,000 population) (2). Brain tumors 
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of children consistently is on the second place among structure of pediatric oncological 
pathology with the 11% share. A rate of pediatric glioblastoma within Post Soviet countries 
fluctuates between 0.12 in Kyrgyzstan up to 2.7 in Republic of Belarus (30). Overall, 
prevalence of glioblastoma among children in Kazakhstan also increased from 0.5 to 1.16 
cases per 100,000 children population in the past 20 years. The highest rates of childhood 
glioblastoma can be seen in regions such as Pavlodar, Zhambyl regions, where rates 
achieved 3.0 cases per 100,000 population (30).   
 
1.5 Aims of the study  
Primary aim 
 
• To investigate association of IDH mutation with the molecular markers of 
tumor tissue, and its effect on glioma patients survival. 
 
Secondary aim 
 
• To investigate prognostic significance of preoperative blood markers for 
survival of patients with glioma. 
• To test each molecular marker for association with preoperative blood 
markers. 
• To investigate whether there is an association between blood parameters, and 
molecular markers for survival of glioma patients. 
 
It was already mentioned that many factors are associated with survival time of 
glioma patients. This study focuses on factors such as age, gender, level of glioma grade, 
survival time after enrollment to the study, presence of mutated genes among patients, 
Karnovski Performance Score, and complex of blood and molecular markers.  Findings of 
the study may benefit professionals in clinical settings to offer better treatment interventions 
for patients with developed gliomas. Importance of the study could be seen in its 
accessibility, and relatively low costs of prognosis central nervous system cancers. 
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 2. Methodology     
This is a historical cohort study that is performed using secondary data provided by 
National Center for Neurosurgery (NCN) (Astana, Kazakhstan). The participants of the study 
were recruited through 2009-2012 from NCN. This is also a more analytical study, since in 
addition to presenting descriptive characteristics of the study cohort, it aims at analyzing the 
association of blood and molecular markers with the overall survival time of the patients after 
surgical treatment procedures. 
 
Target population of the study includes patients diagnosed with glioma. Sampling 
frame includes patients who were surgically treated at the National Center for Neurosurgery 
between 2009-2012 in Astana. Study population includes glioma patients who met exclusion 
and inclusion criteria. The following inclusion criteria were applied to select the study 
population: 
 
1. Patients who were treated at NCN from 2009 to 2012 years.  
 
2. Patients with histopathological confirmed brain tumor (In accordance with WHO 
classification, 2007). 
4. Patients with preoperative full blood count (FBC) analysis. 
5. Absence of active infection and autoimmune disorders. 
 
Exclusion criteria: 
 
1. Patients with missing survival time information. 
 
2. Patients with no outcome status, or unknown. 
 
Rationale for choosing the study population 
 
Current study focused on the patients with same characteristics and study population 
can be considered as homogenous.   In addition, outcome variable was survival status of the 
patients (whether patient alive or dead) by the last follow up time. Out of 202 patients enrolled 
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in this study, only 190 patients were included to final data. The reasons of excluding 12 
participants were absence of information regarding our outcome of interest, and repeated 
information resulting from typing error. 
After defining final sample size, it was possible to calculate power of the test that will 
be used during the analysis. We assumed two sided significance level at 0.05, with sample 
size 190. Finally, power of the test was equal to 0.78.  
 
3. Ethical Considerations 
 
Ethical Committee of the NCN is approved a study with the document “IORG0008395”. 
All ethical procedures were taken into account while collecting data, signed consent forms 
were obtained from patients or from their legal representative in case of patient’s incapacity. 
Afterwards, the Institutional Research and Ethics Committee of Nazarbayev University School 
of Medicine reviewed and approved the study to analyze anonymized secondary data provided 
by NCN. Further safety measures were ensured by storing electronic data in a password-
protected computer, and avoiding transmitting the data via email or other types of transmission 
devices. Data is planned to be used only in research purposes, and will be destroyed after three 
years. 
4. Analysis 
  
In this study statistical analysis was performed using statistical package STATA 12 
(STATA Corporation, USA, Texas, 2012), and statistical significance was determined using 
p-value less than 0.05. After appropriate data management descriptive statistical analysis was 
performed characterizing numeric variables in terms of mean and standard deviation, while 
categorical variables were given in frequencies.  
Some numeric variables such as age, and blood markers were categorized into groups 
considering classification in previous studies (21). Age of patients with glioma diagnosis 
categorized in two groups: those who are less than 45 years and those who are older than 45 
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years. There are 4 grades of glioma, but studies suggest excluding the first grade glioma from 
the study because of its rareness in a population (32). 
 Karnovski Performance Score was categorized into two groups: >70 meaning higher 
capability of functional status of patient, and <70 was considered as low degree of 
functionality. Blood counts such as NLR, ESR, PLT, and molecular markers as vascular 
endothelial growth factor (VEGF), and C-reactive protein (CRP) were categorized taken into 
account cutoff levels used in previous studies (32). RDW variable was considered in two 
categories: patients with RDW<14, versus RDW>14. The association between PLR variable 
and the outcome variable was tested among groups who have PLR<175 versus those with 
PLR>175. Studies suggest that association of VEGF with outcome of interest should be 
compared among three categories including: VEGF<7, VEGF≥7, and with no VEGF (21). 
CRP was also considered in two categories: patients with CRP<5, versus CRP≥5. 
Pearson’s product-moment correlation coefficient and Spearman’s rank correlation 
coefficient were used to determine bivariate relationships between numeric variables.  
Chi-square test was applied to examine bivariate associations between categorical 
variables. Variables were considered as a significant predictor if p-value was less than 0.05, 
and assumptions of the performed test were not violated (at least one observation in each cell). 
Log-rank test were performed to compare survival times between groups within categorical 
variables.  Kaplan-Meier survival analysis method was used to determine median survival 
time, and to compare patients’ overall survival length. 
 
Before conducting Cox-regression, all of the listed assumptions were considered, and 
most of the assumptions were not violated by the study design. In addition, log(h(t)/h0(t)) is a 
linear function of X's assumption was tested with each numeric predictive parameter. 
Furthermore, it should be highlighted that main assumption for Cox-regression is the 
proportional hazard over the period of time. Significant variables and important confounding 
factors, and predictors that considered being important during the bivariate analysis were 
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included to our final model. The multivariate analysis was obtained using Cox proportional 
hazard regression and considering interactions, and avoiding multicollinear variables.  
 
 
5. Results 
 
 
Descriptive characteristics of the data are illustrated in Table1. The total sample size 
was 190 patients diagnosed with glioma. Mean age of patients was 43±12.8 years, and there 
was equal distribution of both genders: 56.3% males, 43.7% females. Those who were younger 
than 45 years were 53.1%.  
One of the important variables in the data set was information on patient’s glioma grade. 
There were no patients with first grade of glioma. 25 patients (13.1%) had second grade glioma 
diagnosis, 71 patients (37.4%) had third level of glioma grade, and 94 participants were 
confirmed with the fourth grade of glioma (49.5%). IDH (isocitrate dehidrogenase) mutation 
genes were present in 85 participants (49.1%), and 88 participants (50.9%) did not have IDH 
mutation. Karnovski Performance Score (KPS) average score of all participants was equal to 
65.3±8.1. Almost two thirds of patients (62.1%) had KPS lower than 70. Average level of CRP 
was 4.6 mg/L, 133 patients (70%) had CRP below 5 mg/L. Average survival time in this cohort 
was 13.8±8.6 months, where at the end of the last follow up 91 (48%) of study participants 
died.   
Bivariate analysis (log-rank test) was performed between variables survival status of 
patients (status) and with each independent variable. However, only two predictors: G (Glioma 
grade) variable was found to be significantly associated with survival time (p=0.0433), as well 
as RDW (Red Cell distribution width) variable (p=0.011). Surprisingly important risk factors 
mentioned in literatures such as age (p=0.7929), gender (p=0.4435), KPS (p=0.7208), NLR 
(p=0.1849) were not associated with survival in this study.   
Further, results of chi-square test revealed that variables KPS (p=0.005), ESR 
(p=0.002), PLT (p=0.021), RDW (p=0.030), PLR (p=0.036), and NLR (p=0.046) were 
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significantly associated with IDH mutation. In contrast, variable G (Glioma grade) was not 
associated with the IDH mutation p=0.065 and 88 (46%) patients were IDH positive. 
Kaplan-Meier method of survival analysis was used to compare overall survival time 
between the IDH positive and IDH negative patients. As illustrated in Graph 1, overall survival 
time is comparatively longer in IDH negative patients than in IDH positive patients. Among 
the patients with glioma both groups (IDH positive, and negative) have approximately equal 
median survival time about 25 months.  
Results of Cox-regression revealed no significant predictors in multivariate analysis.  
Unadjusted HR of dying among glioma patients with IDH versus without IDH was found to be 
HR 1.28 (95% CI: 0.790; 1.901). Final survival model included only IDH mutation, age and 
gender variables. 
6. Discussion     
Primary aim of the study was to assess the importance of the IDH mutation in 
predicting survival for a given cohort of the patients. Previous studies found that IDH mutation 
genes are key process in the development gliomas and other type central nervous system 
tumors (29). Research conducted by Bleeker et al., in 2010 applied DNA samples obtained 
from frozen glioma specimens, and studied survival and enzyme activity. After adjusting for 
KPS, extent of surgical resection, chemotherapy, and dosage of received radiotherapy, IDH 
mutational status was found to be an independent risk factor of overall survival of glioma 
patients (28). However, in this study IDH was not significantly associated with outcome 
variable (survival status of the patient by the end of study). It is important to mention that 
bivariate analysis of   risk factors with survival length (log-rank test) includes time element of 
survival analysis, which is why most of the predictive variables did not show association with 
outcome variable. 
The bivariate analysis of IDH with other predictive variables found some interesting 
results. For example, KPS was significantly associated with IDH (p=0.005), meaning that 
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presence of the mutated genes can significantly affect preoperative physical condition of the 
patient. Regardless of the results on final model it should be highlighted that significant 
associations were found between IDH, and blood markers. There were not any studies 
investigating for the association of the IDH with blood parameters. For example, NLR 
(p=0.046), ESR (p=0.002), PLT (p=0.021), and RDW (p=0.0034) were significantly 
associated with IDH mutation genes among glioma patients.  
As it was mentioned in previous parts glioma has poor prognosis and short survival 
time equal to 13-15 months on average (14,17,21). In current study median survival time 
found to be longer–22 months (95% CI 0.3408-0.6690). However, it does not necessarily mean 
that patients treated at NCN have longer survival time. Possible explanation might be absence 
of data when surgical intervention was applied or the time when patients acquired 
chemotherapy.  
Similar to other studies, current study found significant association between survival 
status of the patients and stage of the glioma grade (11,13). Previous studies revealed that there 
is a significant difference in survival length considering glioma grades of the patient. Cox-
Regression analysis showed that glioma grade is significant predictor of the survival time of 
the patients (p=0.017, and with 95% CI 0.2750-0.8830). In addition, significant difference was 
found in survival among all three stages of glioma grade (p=0.0464). However, tests revealed 
that glioma grade variable might be mediating variable, and its significance can be enhanced 
by its indirect effect on the outcome.  
Several studies concluded that age and preoperative performance status (KPS) 
significantly affect the prognosis of the survival of the glioma patients (16,17, 8). However, 
current study did not find significant predictive characteristics of the KPS on survival 
((p=0.7208).  
Importance of the C-reactive protein for glioma patient’s survival was mentioned in 
studies conducted by Matthias et al., (2013). However, current study did not find any 
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association between the survival of the glioma patients and CRP (p=0.07). In addition, we 
were interested to test an association between IDH mutation and CRP. In this case the analysis 
results also showed no association between CRP and IDH mutation (p=0.227). 
Numerous studies proposed significance of the inflammatory markers for glioma 
survival (15). One of the routinely studied blood parameters is considered to be NLR 
(neutrophil-lymphocyte ratio). Meta-analysis of 100 researches including overall 40,559 
sample size, revealed optimal cutoff value of 4.0 (23). Considering all suggestions of previous 
studies, we tested significance of following blood parameters: NLR, ESR, PLT, RDW. Results 
were as follows: during the bivariate analysis only RDW was significantly associated with 
outcome variable (p=0.0118). However, during the multivariate analysis RDW became less 
informative predictor, and was not included in the final model.  
It should be mentioned that current study did not find association between survival 
status and age, which verify findings of previous studies (26). Research shows that glioma 
diagnoses is more common in men compared to women, and that men also have shorter 
survival time. However, this study no difference in length of survival was revealed between 
gender (p=0.06) groups (HR1.24, 95% CI: 0.788-1.980) (Table 4).  
Despite the fact that current study did not find any significant predictors of survival for 
a given population, various types of sophisticated statistical analysis were used. Nevertheless, 
further studies are needed to assess effect of biological markers on glioma patient’s survival. 
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7. Study limitations 
 
Current study on survival analysis among glioma patients has several limitations that 
should be taken into account. Firstly, secondary data used in this study may have information 
bias, because current researcher did all analysis relying on correctness of the provided data. 
Secondly, it is believed that due to lack of the data current study did not find significant 
predictors for survival of glioma patients. Literature suggests that absence of information on 
tumor size, tumor location, or important clinical interventions (such as chemotherapy) can be 
important confounding factors (10,12,13).  
 
 
8. Conclusion and recommendation 
 
It was proved by previous studies that biological markers and their preoperative 
characteristics may serve as an important information for prognosis of the disease. Furthermore, 
available information on biological markers assists tailoring treatment strategy considering 
specific biological characteristics of patients. This study also recommends implementing further 
research on survival of the glioma patients by looking at the effect of the potential confounders 
such as size or volume of the tumor, tumor location, and information of whether patients 
acquired chemotherapy or not. The information from this study can be beneficial for treatment 
planning, prognosis, and it also opens a new avenue for further research in this sphere.  
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APPENDIX LIST 
 
Table1. Descriptive statistics of variables 
Parameters Patient number (%) 
Age  
<45 
≥45 
101 (53.1) 
89 (46.9) 
Sex 
Male  
female 
107 (56.3) 
83 (43.7) 
G 
2 
3 
4 
25 (13.1) 
71 (37.4) 
94 (49.5) 
Survival status 
Alive  
Died 
99 (52) 
91 (48) 
KPS 
<70 
≥70 
72 (37.9) 
118 (62.1) 
IDH 
No mutation 
mutation 
85 (49.1) 
88 (50.9) 
NLR 
<4 
≥4 
134 (70.5) 
56 (29.5) 
ESR 
<15 
≥15 
135 (71.1) 
55 (28.9) 
PLT 
<350 
≥350 
183 (96.3) 
7 (3.7) 
VEGF 
no 
<7 
≥7 
11 (6.4) 
70 (40.4) 
92 (53.2) 
RDW 
<14 
≥14 
145 (76.3) 
45 (23.7) 
PLR 
<175 
≥175 
132 (69.5) 
58 (30.5) 
CRP 
<5 
≥5 
133 (70.0) 
57 (30.0) 
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Table2. Bivariate analysis of each parameters with outcome variable (survival status) 
Risk Factors 
Survival status  
% (n) p-value 
alive died 
Age  
 
<45 
≥45 
 
 
62 (61.4) 
37 (41.6) 
 
 
 
39 (38.6) 
52(58.4) 
0.7929 
Sex  
Male 
Female 
 
63 (58.9) 
36 (43.4) 
 
44 (41.1) 
47 (56.6) 
 
0.44356 
G  
 
2 
3 
4 
 
 
23 (92.0) 
47 (66.2) 
29 (30.85) 
 
 
2 (8.0) 
24 (33.8) 
65 (69.15) 
 
 
 
 
0.0433 
KPS  
<70 
≥70 
 
24 (33.3) 
75 (63.6) 
 
 
48 (66.7) 
43 (36.4) 
 
 
0.7208 
IDH  
 
mutation 
no mutation 
 
 
 
56 (63.6) 
32 (37.7) 
 
 
 
32 (36.4) 
53 (62.3) 
 
 
 
0.3510 
NLR  
<4 
≥4 
 
 
72 (53.7) 
27 (48.2) 
 
 
62 (46.3) 
29 (51.8) 
 
 
0.1849 
ESR  
 
<15 
≥15 
 
 
  84 (62.2) 
15 (27.3) 
 
 
 
51 (37.8) 
40 (72.7) 
 
 
 
0.7761 
PLT  
<350 
≥350 
 
 
 
 
97 (53.0) 
2 (28.6) 
 
 
 
 86 (47.0) 
5 (71.4) 
 
 
 
 
0.1303 
 
VEGF  
 
no 
<7 
≥7 
 
 
 
 
6 (54.6) 
35 (50) 
47 (51.0) 
 
 
 
5 (45.4) 
35 (50.0) 
45 (49.0) 
 
 
 
 
0.1479 
22 
 
RDW  
 
<14 
≥14 
 
 
76 (52.4) 
23 (51.1) 
 
 
69 (47.6) 
22 (48.,9) 
 
 
0.0118 
PLR  
 
<175 
≥175 
 
 
73 (53.3) 
26 (44.8) 
 
 
59 (44.7) 
32 (55.2) 
 
 
0.1585 
CRP  
 
<5 
≥5 
 
 
76 (57.1) 
23 (40.4) 
 
 
57 (42.9) 
34 (59.6) 
 
 
0.0669 
 
 
 
Table3. Bivariate analysis of each parameters with IDH (mutated genes) 
Risk Factors 
IDH 
% (n) p-value 
Yes  NO 
Age  
 
<45 
≥45 
 
 
43 (48.3) 
45 (53.6) 
 
 
 
46 (51.7) 
39(46.4) 
0.489 
Sex  
Male 
Female 
 
48 (49.5) 
40 (52.6) 
 
49 (50.5) 
36 (47.4) 
 
0.681 
G  
 
2 
3 
4 
 
 
14 (66.7) 
36 (57.1) 
38 (42.7) 
 
 
7 (33.3) 
27 (42.9) 
51 (57.3) 
 
 
 
 
0.065 
KPS  
<70 
≥70 
 
25 (37.3) 
63 (59.4) 
 
 
42 (62.7) 
43 (40.6) 
 
 
0.005 
NLR  
<4 
≥4 
 
 
69 (55.7) 
19 (38.8) 
 
 
55 (44.3) 
30 (61.2) 
 
 
0.046 
23 
 
ESR  
 
<15 
≥15 
 
 
  75 (58.1) 
11 (29.7) 
 
 
 
54 (41.9) 
26 (70.3) 
 
 
 
0.002 
PLT  
<350 
≥350 
 
 
 
88 (52.4) 
0 (00.0) 
 
 
 80 (47.6) 
5  (100.0) 
 
 
 
 
0.021 
 
VEGF  
 
no 
<7 
≥7 
 
 
 
 
4 (36.4) 
34 (48.6) 
50 (54.4) 
 
 
 
7 (63.6) 
36 (51.4) 
42 (45.6) 
 
 
 
 
0.468 
RDW  
 
<14 
≥14 
 
 
79 (54.5) 
9 (32.1) 
 
 
66 (45.5) 
19 (67.9) 
 
 
0.030 
PLR  
 
<175 
≥175 
 
 
73 (55.3) 
15 (36.6) 
 
 
59 (44.7) 
26 (63.4) 
 
 
0.036 
CRP  
 
<5 
≥5 
 
 
71 (53.4) 
17 (42.5) 
 
 
62 (46.6) 
23 (57.5) 
 
 
0.227 
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Table4. Results of Multivariate (Cox-Regression) 
Risk factors Hazard Ratio 95% Confidence Interval 
IDH 1.27 (0.784; 2.084) 
Age 1.06 (0.677; 1.683) 
Sex  1.24 (0.788; 1.980) 
NLR 0.68 (0.412; 1.138) 
ESR 1.3 (0.606; 2.808) 
CRP 1.05 (0.520; 2.137) 
 
 
 
 
Graph1. Kaplan-Meier method: comparison of survival time between IDH positive and IDH 
negative groups
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